Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross BTK inhibitors Coverage Update |…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.590

    Bruton Tyrosine Kinase Inhibitors (BTK inhibitors)

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.590 alerts

    Get alerted when Policy 5.01.590 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Pharmacy coverage policy for Bruton Tyrosine Kinase inhibitors intended to guide pharmacy prior-authorization and utilization management, including agent-specific criteria, dose and quantity limits, and initial/re-authorization durations.

    Policy Summary
    PayerPremera Bluecross
    PolicyBruton Tyrosine Kinase Inhibitors (BTK inhibitors)
    Policy CodePolicy 5.01.590
    Change TypeCoverage and operational updates (added indications, dose/quantity limits, authorization durations)
    Effective DateAug. 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug. 1, 2026
    Key ActionSubmit prior authorization through the pharmacy benefit with documentation of age, indication-specific criteria, prior therapies, and adherence to dose/quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    Updated initial authorization duration for most BTK agents (Brukinsa, Calquence, Imbruvica, Jaypirca) from 3 months to 6 months and for Rhapsido and Wayrilz to 12 months.

    Added a dose limitation for Brukinsa (zanubrutinib) limiting dosage to 320 mg daily.

    Added coverage criteria for Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) with insufficient response to prior treatment.

    Updated coverage criteria for Rhapsido (remibrutinib) based on phase 3 REMIX trials for chronic spontaneous urticaria (CSU).

    Clarified that medications listed are subject to FDA dosage and administration prescribing information and that non-formulary exception authorizations may be approved up to 12 months.

    Updated Jaypirca (pirtobrutinib) criteria for relapsed or refractory CLL/SLL removing the requirement of 2 prior lines of therapy including a BCL-2 inhibitor.

    Updated Imbruvica (ibrutinib) coverage criteria to limit use to adults and adjusted chronic graft-versus-host disease age criteria to 1 year and older.

    Added or updated dose/quantity limits: Brukinsa (zanubrutinib) dose limited to 320 mg daily and quantity limited to 60 tablets per 30 days; Wayrilz (rilzabrutinib) quantity limited to 60 tablets per 30 days; Imbruvica tablet/capsule/suspension quantity limits added.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5.01.590policy identifier
    Aug 1, 2026effective date
    6 moinitial auth (most agents)
    12 moinitial auth (remibrutinib/rilzabrutinib)
    60/30dcommon qty limit
    ≥18adult minimum age

    Coverage Criteria

    Initial Therapy — Brukinsa (zanubrutinib)

    Brukinsa (zanubrutinib) — Covered when ALL of the following are met

    Brukinsa (zanubrutinib) initial criteria: The individual is aged 18 years or older AND meets one of: diagnosed with mantle cell lymphoma (MCL) and has received at least 1 prior therapy; OR diagnosed with Waldenström's macroglobulinemia (WM); OR diagnosed with relapsed or refractory marginal zone lymphoma (MZL) and has received at least 1 anti-CD20-based regimen (e.g., rituximab); OR diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); OR diagnosed with relapsed or refractory follicular lymphoma when Brukinsa will be used in combination with obinutuzumab after 2 or more lines of systemic therapy. Additionally: dose is limited to 320 mg daily AND quantity is limited to 60 tablets per 30 days.dose 320 mg daily; qty 60 tabs/30 days

    Initial authorization duration per policy update: 6 months for Brukinsa.

    Initial Therapy — Calquence (acalabrutinib)

    Calquence (acalabrutinib) — Covered when ALL of the following are met

    Calquence (acalabrutinib) general criteria: The individual is aged 18 years or older AND meets one of the agent-specific indications including BTK inhibitor–naïve adults with relapsed or refractory mantle cell lymphoma (MCL) who have tried at least 1 prior chemotherapy regimen or stem-cell transplant; or previously untreated MCL in individuals ineligible for autologous HSCT when used in combination with bendamustine and rituximab; or other labeled indications as described in policy. Additionally: dose limited to 320 mg daily AND quantity limited to 60 tablets per 30 days.dose 320 mg daily; qty 60 tabs/30 days

    Initial authorization duration per policy update: 6 months for Calquence.

    Initial Therapy — Imbruvica (ibrutinib)

    Imbruvica (ibrutinib) — Covered when ALL of the following are met

    Imbruvica (ibrutinib) criteria: The individual is aged 18 years or older AND meets one of: diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with or without 17p deletion; OR diagnosed with Waldenström macroglobulinemia; OR other labeled indications. Quantity limits vary by formulation: 70 mg capsule — 30 capsules per 30 days; 140 mg capsule — 90 capsules per 30 days; 140 mg/280 mg/420 mg tablet — 30 tablets per 30 days; 70 mg/mL suspension — 216 mL per 30 days. Imbruvica is also medically necessary for chronic graft-versus-host disease (cGVHD) when age ≥1 year and after failure of ≥1 line of systemic therapy (same quantity limits apply).formulation-specific quantity limits

    Initial authorization duration per policy update: 6 months for Imbruvica; quantity limits added per 30 days.

    Initial Therapy — Jaypirca (pirtobrutinib)

    Jaypirca (pirtobrutinib) — Covered when ALL of the following are met

    Jaypirca (pirtobrutinib) MCL and CLL/SLL criteria: The individual is aged 18 years or older AND for mantle cell lymphoma (MCL): has relapsed or refractory MCL after at least 2 lines of systemic therapy and has been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor (e.g., acalabrutinib, ibrutinib, zanubrutinib). For chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): covered when the individual has been previously treated with a BTK inhibitor. Formulation-specific quantity limits apply.prior 2 lines (MCL) and prior BTK exposure (MCL); prior BTK exposure (CLL/SLL)

    Policy history: requirement for 2 prior lines including a BCL-2 inhibitor was removed for certain CLL/SLL criteria per updates.

    Initial Therapy — Rhapsido (remibrutinib)

    Rhapsido (remibrutinib) — Covered when ALL of the following are met

    Rhapsido (remibrutinib) CSU criteria: The individual is aged 18 years or older AND has chronic spontaneous urticaria (CSU) with symptoms for at least 6 weeks AND no evidence of another cause of urticaria AND has failed or been intolerant to at least 2 H1 antihistamines at high doses (up to 4× standard dosing) OR maximum tolerated dose AND has had an inadequate response or intolerance to omalizumab AND plans to continue a low-dose H1 antihistamine. Medication must not be used in combination with dupilumab (Dupixent) or omalizumab when used for chronic urticaria; must not be used with antiplatelet/anticoagulant therapy; individual must not have a bleeding disorder or hepatic impairment; medication prescribed by or in consultation with an allergist/immunologist or dermatologist. Dose limited to 25 mg twice daily AND quantity limited to 60 tablets per 30 days.dose 25 mg BID; qty 60 tabs/30 days

    Initial authorization duration per policy update: 12 months for Rhapsido.

    Initial Therapy — Wayrilz (rilzabrutinib)

    Wayrilz (rilzabrutinib) — Covered when ALL of the following are met

    Wayrilz (rilzabrutinib) general initial criteria: The individual is aged 18 years or older AND meets the agent-specific indication criteria below; medication is subject to safety exclusions (not used in combination with antiplatelet or anticoagulant therapy; individual does not have a bleeding disorder or hepatic impairment). Quantity limited to 60 tablets per 30 days. Initial authorization duration per policy update: 12 months for Wayrilz.qty 60 tabs/30 days

    See non-hematology and hematology-specific dosing nodes for dose differences.

    Wayrilz — non-hematology indication

    Covered when ALL of the following are met for non-hematology immune/dermatology indication (Wayrilz 25 mg BID):

    General safety and prescriber: Medication is not used in combination with antiplatelet or anticoagulant therapy; the individual does not have a bleeding disorder (e.g., hemophilia A or B, von Willebrand Disease, or Factor XI deficiency); the individual does not have hepatic impairment; medication is prescribed by or in consultation with an allergist/immunologist or dermatologist.
    Dose and quantity limits: Dose limited to 25 mg twice daily; quantity limited to 60 tablets per 30 days.
    Age: Individual is aged 18 years or older.

    Wayrilz — ITP (hematology) indication

    Covered when ALL of the following are met for Wayrilz in persistent or chronic immune thrombocytopenia (hematology indication):

    Age: Individual is aged 18 years or older.
    Platelet criteria: Has a platelet count < 30,000/μL OR has a platelet count < 50,000/μL and has an increased risk for bleeding.
    Prior therapy failure: Has had an insufficient response to corticosteroids, immunoglobulins (IVIG), rituximab, or splenectomy.
    Prescriber and dosing: Medication is prescribed by or in consultation with a hematologist or oncologist; dose limited to 400 mg twice daily; quantity limited to 60 tablets per 30 days.

    Investigational uses

    Investigational / Not covered

    Other uses: All other uses of the medications listed in this policy are considered investigational.

    Selected indication evidence and related coverage in this document portion

    Coverage is informed by FDA-approved indications and pivotal trial evidence; selected examples from this part of the policy:

    Brukinsa in Mantle Cell Lymphoma (MCL): Brukinsa demonstrated an ORR of 84% in single-arm Phase 2 (BGB-3111-206) and similarly in Phase 1/2 (BGB-3111-AU-003); trial dosing was 160 mg twice daily or 320 mg daily and policy limits Brukinsa to 320 mg daily.

    Supports coverage for previously treated MCL per label when criteria met.

    Brukinsa in Marginal Zone Lymphoma (MZL): Single-arm Study BGB-3111-214 showed ORR 67% (CR 26%) in previously treated MZL after at least one anti-CD20 regimen, supporting coverage for MZL per policy criteria.
    Wayrilz (rilzabrutinib) for chronic ITP: FDA approval for Wayrilz in adults with persistent or chronic ITP was based on Phase 3 LUNA 3 where durable platelet response at Week 24 was 23.3% with Wayrilz versus 0% with placebo, supporting the policy addition of Wayrilz criteria.
    Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU):

    The extracted policy text in this section cross-references other Premera drug approval policies but does not list additional explicit coverage exclusions beyond those detailed for individual agents. See agent-specific criteria for contraindications, dosing, and quantity limits. Providers should follow referenced policies (for example, Policy 5.01.556 and Policy 5.01.566) where applicable when evaluating coverage for related therapies.

    For agents used to treat chronic spontaneous urticaria or related dermatologic/allergic conditions (for example remibrutinib/Rhapsido and rilzabrutinib/Wayrilz in non-hematology indications), the policy expressly prohibits concurrent use with dupilumab (Dupixent) or omalizumab (Xolair) when those agents are being used to treat chronic urticaria. Related medical policies (5.01.513 and 5.01.575) were added to the policy cross-reference list in the 2026 update.

    Safety-related exclusions specified in the agent criteria include concurrent use with antiplatelet or anticoagulant therapy, a documented bleeding disorder (examples cited: hemophilia A or B, von Willebrand Disease, Factor XI deficiency), and hepatic impairment. These conditions are listed as exclusions from meeting the medical necessity criteria for the affected indications and may require specialist prescribing or consultation per the drug-specific criteria.

    Per the 2023 policy review, Imbruvica (ibrutinib) indications for Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL) were removed from this policy to align the policy with contemporaneous FDA label changes.

    This medical policy is a guide for determining medical necessity and does not apply to Medicare Advantage plans. Providers and reviewers must verify member-specific benefit limitations by consulting the member benefit booklet or contacting customer service.

    Within the excerpted document text there are no explicit generic statements labeled 'not medically necessary' beyond the investigational-use language; individual agent criteria and exclusions define when therapy does not meet medical necessity.

    The policy states that all other uses of the medications listed are considered investigational. That investigational classification informs coverage decisions for indications not explicitly enumerated in the drug-specific criteria.

    Consistent with the policy language, investigational uses are treated as not meeting the drug-specific medical necessity criteria; where an indication is not listed in the criteria the medication is considered investigational and therefore would not be approved under this policy absent an exception.

    Initial Therapy — Drug Specific Criteria

    Initial Therapy — Drug-specific

    Initial authorization rules per drug and indication

    Initial authorization general: Drug-specific initial authorization is available when all listed indication and prior therapy requirements are met; dose and quantity limits apply per drug/formulation. Initial approval durations vary by drug as specified in policy updates.see drug-specific nodes

    Prior authorization is required through the pharmacy benefit; documentation of age, diagnosis, prior therapies, and specialist prescribing as applicable should be submitted.

    Wayrilz initial therapy

    Initial authorization requirements for Wayrilz

    Non-hematology initial: Medication not used with antiplatelet/anticoagulant therapy; no bleeding disorder; no hepatic impairment; prescribed by or in consultation with an allergist/immunologist or dermatologist; dose 25 mg twice daily; quantity limited to 60 tablets per 30 days; age ≥18 years.

    Re-authorization and Continuation Criteria

    Re-authorization

    Re-authorization

    Re-authorization conditions: Re-authorization of all drugs listed may be approved up to 12 months provided drug-specific coverage criteria are met and chart notes/documentation demonstrate continued positive clinical response to therapy.up to 12 months

    Providers should submit office visit notes documenting diagnosis, relevant history, physical evaluation, medication history, and objective evidence of clinical benefit.

    Re-authorization rules

    Re-authorization rules

    Re-authorization general: Re-authorization requires that drug-specific criteria continue to be met and that documentation (chart notes) shows a sustained positive clinical response; approvals may be granted up to 12 months when criteria are satisfied.

    What Providers Must Do

    Prior Authorization

    Prior authorization applies

    This policy is applied to pharmacy-managed Bruton Tyrosine Kinase (BTK) inhibitors and is used in prior authorization decisions for the agents listed in the policy; providers must initiate prior authorization through the pharmacy benefit when requesting coverage for these medications.

    • Prior authorization is required for BTK inhibitors per this medical policy.
    • Provider should submit PA requests via the pharmacy benefit channel.
    Prior Authorization

    Prior authorization referenced but not specified

    The document references prior authorization routing and related Premera drug approval policies but does not provide a single, concrete PA form or code-specific checklist in this excerpt; providers should note the policy refers to other Premera policies for related approval details.

    • Policy text repeats cross-references to related policies (e.g., 5.01.556, 5.01.566) for related approval context.

    Coding

    Codingmixed
    No codes listed

    Step Therapy and Prior Treatment Requirements

    RequirementNotes / Evidence
    Documentation of prior lines of systemic therapy when required by the agent-specific criteria (e.g., Brukinsa for MCL requires ≥1 prior therapy; Jaypirca for MCL requires ≥2 prior systemic therapies).
    Documentation of prior exposure to a BTK inhibitor when specified by the agent criteria (e.g., Jaypirca and some Jaypirca/CLL or pirtobrutinib criteria require prior BTK inhibitor exposure).
    RequirementNotes / Evidence
    Must document insufficient response to corticosteroids, immunoglobulins (IVIG), rituximab, or splenectomy prior to approval for Wayrilz when used for ITP.
    Wayrilz approval for persistent or chronic ITP was based on LUNA 3 showing durable platelet response (23.3% vs 0% at Week 24); policy requires prior treatment failure before coverage.
    Policy statementSupporting trial / label consistency
    Prior therapy requirements referenced in the policy align with labeled indications and the populations enrolled in pivotal trials (for example, Brukinsa MZL after ≥1 anti‑CD20 regimen).
    Rhapsido CSU criteria require failure of ≥2 high‑dose H1 antihistamines and inadequate response to omalizumab, consistent with REMIX-1/2 trial populations; Wayrilz ITP prior-failure requirements reflect LUNA 3 enrollment of patients with prior insufficient response to prior therapies.
    Agent / IndicationPrior therapy requirement
    Brukinsa (zanubrutinib) — MCL, MZL
    Brukinsa MCL: at least 1 prior therapy; Brukinsa MZL: at least 1 anti‑CD20 regimen (e.g., rituximab).
    Jaypirca (pirtobrutinib) — MCL, CLL/SLL
    Jaypirca MCL: previously treated after ≥2 lines of systemic therapy and prior BTK inhibitor exposure (agent-specific criteria); Jaypirca CLL/SLL: prior BTK inhibitor exposure required for CLL/SLL indications per policy.
    Rhapsido (remibrutinib) — CSU
    Rhapsido CSU: failed or intolerant to ≥2 high‑dose H1 antihistamines and inadequate response or intolerance to omalizumab before initiation; specialist prescribing and safety exclusions apply.
    Wayrilz (rilzabrutinib) — ITP
    Wayrilz ITP: insufficient response to corticosteroids, IVIG, rituximab, or splenectomy required prior to approval; platelet count thresholds specified in policy.

    Quantity and Dose Limits

    Brukinsa / Calquence — quantity limits
    DrugsBrukinsa (zanubrutinib); Calquence (acalabrutinib)
    Monthly quantity limit60 tablets per 30 days
    Dose constraint notedDose limit for zanubrutinib/acalabrutinib: 320 mg daily (Brukinsa dose limited to 320 mg daily)
    Authorization notePrior authorization required; initial authorization updated to 6 months for most BTK agents
    Imbruvica — formulation-specific quantity limits
    DrugImbruvica (ibrutinib)
    Quantity limits (formulation-specific)

    Background

    Bruton’s tyrosine kinase (BTK) inhibitors are oral small-molecule agents that block intracellular BTK signaling pathways important in B‑cell receptor signaling. These agents are used primarily in B‑cell malignancies and, in recent FDA-labeled approvals, select immune-mediated disorders. The policy covers multiple BTK inhibitors and provides agent- and indication-specific criteria reflecting labeled indications, trial evidence, dosing constraints, safety exclusions, and specialist prescribing requirements.

    Definitions and Abbreviations

    Referenced policies — Rituximab / Pharmacotherapy of Thrombocytopenia
    Referenced policiesRituximab: Non-oncologic and Miscellaneous (Policy 5.01.556); Pharmacotherapy of Thrombocytopenia (Policy 5.01.566)
    Additional related policiesOmalizumab Products (5.01.513); Dupixent (dupilumab) (5.01.575)
    UseThese related policies are cited for management of prior therapies and specific treatment pathways referenced in BTK inhibitor criteria
    BTK inhibitors — short definition
    TermBTK inhibitors
    Short definitionBruton's tyrosine kinase inhibitors — small-molecule agents that bind to the intracellular domain of Bruton's kinase used in targeted therapy

    Site of Care

    Note

    Managed through pharmacy benefit (home)

    Site of care: these medications are managed through the pharmacy benefit (home administration/dispense handled via pharmacy processes).

    Revision History

    2018-11-01policy_created

    New policy created and approved (transferred ibrutinib and acalabrutinib from Policy 5.01.534 and updated indications per labels).

    2020-04-01criteria_added

    Added criteria for Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL).

    2023-03-01criteria_added

    Added coverage for Jaypirca (pirtobrutinib) for relapsed or refractory MCL and added Brukinsa indication for adults with CLL/SLL.

    Policy Summary
    PayerPremera Bluecross
    PolicyBruton Tyrosine Kinase Inhibitors (BTK inhibitors)
    Policy CodePolicy 5.01.590
    Change TypeCoverage and operational updates (added indications, dose/quantity limits, authorization durations)
    Effective DateAug. 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug. 1, 2026
    Key ActionSubmit prior authorization through the pharmacy benefit with documentation of age, indication-specific criteria, prior therapies, and adherence to dose/quantity limits.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy — Drug Specific CriteriaRe-authorization and Continuation CriteriaWhat Providers Must DoCodingStep Therapy and Prior Treatment RequirementsQuantity and Dose LimitsBackgroundDefinitions and AbbreviationsSite of CareRevision History
    REMIX-1 and REMIX-2 Phase 3 trials (total N≈925) enrolled CSU patients inadequately controlled despite 2nd-generation H1 antihistamines and showed statistically significant improvements in itch and hives versus placebo, supporting coverage for CSU when criteria are met.

    Initial authorization updated to 12 months for Rhapsido per 2026 review.

    Hematology initial: Age ≥18 years; platelet criteria met (<30,000/μL OR <50,000/μL with increased bleeding risk); insufficient response to corticosteroids, immunoglobulins, rituximab, or splenectomy; prescribed by or in consultation with a hematologist or oncologist; dose limited to 400 mg twice daily; quantity limited to 60 tablets per 30 days.

    Initial therapy evidence nodes

    Initial therapy evidence summaries from pivotal trials inform coverage for specific indications.

    Brukinsa initial therapy/indication context: Brukinsa trials used dosing of 160 mg twice daily or 320 mg daily until progression or toxicity and showed high ORR in MCL and activity in other B-cell malignancies; policy limits dose to 320 mg daily.

    BGB-3111-206 and BGB-3111-AU-003 support efficacy in previously treated MCL.

    Wayrilz initial therapy/indication context: LUNA 3 randomized placebo-controlled trial in adults with persistent/chronic ITP demonstrated statistically significant durable platelet responses and faster time to response with Wayrilz versus placebo, supporting FDA approval and coverage criteria.
    Rhapsido initial therapy/indication context: REMIX-1 and REMIX-2 Phase 3 trials in CSU enrolled patients inadequately controlled on 2G H1-AHs and demonstrated significant improvements in itch and hives with remibrutinib versus placebo, informing coverage for CSU when criteria are met.

    Initial authorization durations

    Initial authorization duration updates for agents in this policy

    Initial Authorization Durations: Initial authorization durations updated in 2026: Brukinsa, Calquence, Imbruvica, and Jaypirca — initial authorization up to 6 months; Rhapsido and Wayrilz — initial authorization up to 12 months.

    Authorization duration updates

    Continuation/initial authorization durations updated in 2026 review.

    Authorization duration updates: Per 2026 policy update: most BTK agents (Brukinsa, Calquence, Imbruvica, Jaypirca) initial authorizations updated to 6 months; Rhapsido and Wayrilz initial authorizations updated to 12 months. Re-authorization of all drugs may be approved up to 12 months when criteria are met.

    Operational change affecting pharmacy prior authorization durations.

    Prior Authorization

    Prior authorization cross-reference

    Prior authorization requests may be routed or interpreted in conjunction with Premera related drug approval policies (e.g., 5.01.556 and 5.01.566) as referenced in the policy text; providers should be aware approvals may be guided by those related policies.

    • Cross-reference to Premera policies 5.01.556 and 5.01.566 is present in the policy text.
    Prior Authorization

    Prior authorization required

    Prior authorization is required and approval is contingent on documentation that the patient meets age- and indication-specific criteria (including any required prior therapies or prior BTK inhibitor exposure) and that dose and quantity limits in the policy are followed.

    • Submit documentation that the individual meets the drug-specific indication (age, diagnosis, prior therapies).
    • Ensure requested dosing and quantity do not exceed policy limits (e.g., Brukinsa dose limit and quantity limits).
    Prior Authorization

    Prior authorization via pharmacy benefit

    Requests for medications in this policy must be processed through the pharmacy benefit; approvals are granted for specified initial durations per drug and re-authorization is contingent on meeting drug-specific continuation criteria.

    • PA through pharmacy benefit; managed through pharmacy benefit.
    • Re-authorization contingent on meeting drug-specific criteria and documented clinical response.
    Billing Rule

    Initial authorization duration updates

    Initial authorization durations were updated in the 2026 review: most BTK agents (Brukinsa, Calquence, Imbruvica, Jaypirca) now have a 6-month initial authorization; Rhapsido and Wayrilz initial authorizations are 12 months.

    • Initial authorization: Brukinsa, Calquence, Imbruvica, Jaypirca — up to 6 months.
    • Initial authorization: Rhapsido, Wayrilz — up to 12 months.
    Prior Authorization

    Prior authorization and initial authorization durations

    Prior authorization is required for BTK inhibitors under this medical policy and initial authorization durations were revised (most agents to 6 months; remibrutinib and rilzabrutinib to 12 months); providers should request the appropriate initial length per agent when submitting PA.

    • When submitting PA, indicate the agent-specific requested initial authorization length consistent with the policy update.
    Documentation Required

    Provider submission and supporting documentation

    Providers must submit prior authorization requests with documentation supporting the medical necessity criteria described in the policy (diagnosis, prior therapies, age, dosing, and quantity) — see the Documentation Requirements section for specifics.

    • Include office visit notes documenting diagnosis, relevant history, physical exam, and medication history.
    • Attach documentation of prior therapies or prior BTK exposure when required by the agent-specific criteria.
    Step Therapy

    No step therapy rules stated

    The provided policy text does not state any step therapy (fail-first) program rules beyond agent-specific prior therapy requirements; there are no general step-therapy sequences specified in this excerpt.

    • No universal step therapy rules are specified; follow the agent-specific prior therapy requirements in each drug section.
    Step Therapy

    No step therapy requirements specified

    No additional step therapy requirements are specified in the extracted text; approvals depend on meeting the specific prior-therapy criteria listed under each agent rather than a single step-therapy policy.

    • Check each drug’s criteria for required prior lines or failures rather than expecting a centralized step therapy table in this excerpt.
    Step Therapy

    Prior therapy requirements

    Some indications require documented prior lines of therapy before coverage is approved — for example, Brukinsa for MCL requires at least one prior therapy and Jaypirca for MCL requires prior systemic therapies and prior BTK exposure per the agent criteria.

    • Document prior treatments (e.g., prior anti-CD20 regimen for MZL, prior chemotherapy for MCL) when applicable.
    • For Jaypirca in MCL, document prior systemic therapies and prior BTK inhibitor exposure.
    Step Therapy

    Prior therapy requirement for Wayrilz (ITP)

    For Wayrilz when used for ITP, the policy requires documentation that the individual had an insufficient response to corticosteroids, immunoglobulins, rituximab, or splenectomy before approval.

    • Provide records showing inadequate response to corticosteroids, IVIG, rituximab, or splenectomy.
    Step Therapy

    Step/staged therapy expectations

    Policy references prior therapies consistent with labeled indications and trial populations (e.g., Brukinsa after at least one anti-CD20 regimen for MZL; Rhapsido after failure of 2 H1 antihistamines and omalizumab for CSU); providers must document these prior therapy failures per the listed criteria.

    • For Rhapsido (CSU): document failure/intolerance to at least 2 high-dose H1 antihistamines and inadequate response/intolerance to omalizumab.
    • For Brukinsa (MZL): document prior anti-CD20-based regimen (e.g., rituximab).
    Step Therapy

    Step/previous therapy notes

    Agent-specific prior therapy notes are present and have been updated in some cases (for example, Jaypirca criteria were revised to remove a prior BCL-2 inhibitor requirement for relapsed/refractory CLL/SLL); providers must follow the current agent criteria in the policy when documenting prior therapies.

    • Confirm the current published agent-specific prior therapy requirements in the policy history and document accordingly.
    Documentation Required

    Re-authorization documentation required

    Re-authorization requires submission of chart notes demonstrating continued positive clinical response to therapy; include follow-up visit documentation showing clinical benefit.

    • Provide recent chart notes documenting clinical response to therapy at re-authorization.
    • Re-authorizations may be approved up to 12 months when criteria are met.
    Documentation Required

    Required medical record documentation

    Submit office visit notes that include the diagnosis, relevant history, physical evaluation, and medication history to support medical necessity and the prior authorization request.

    • Office visit notes must document diagnosis, history, physical exam, and medication history.
    Documentation Required

    Required documentation — follow FDA prescribing information

    Prescribers must follow the product's FDA prescribing information; documentation submitted with PA should support the diagnosis, prior therapies, and that the patient meets the drug-specific indication (examples cited in the policy: prior anti-CD20 therapy for MZL; insufficient response to prior ITP therapy for Wayrilz).

    • Follow FDA dosing and administration guidance.
    • Include documentation showing the patient meets drug-specific labeled criteria.
    Note

    Benefit verification prior to PA

    Verify member benefits and any plan-specific limitations before submitting a PA; coverage decisions are subject to the member benefit booklet and plan terms and may affect approval.

    • Consult the member benefit booklet or contact customer service to confirm coverage limits.
    • Policy is a guide; actual coverage depends on member plan terms.
    Note

    No other provider actions specified here

    This section of the document contains no additional provider actions beyond those already specified in the policy excerpts (prior authorization, documentation, and prior therapy requirements); providers should follow the specific drug criteria in the policy when requesting coverage.

    • No other provider actions are specified in this portion of the document.
    Denial Risk

    No explicit authorization denial triggers listed

    The extracted text does not list explicit automatic denial triggers; however, providers should be aware that failure to meet criteria, safety exclusions, dose/quantity limits, or member benefit restrictions may result in denial.

    • No explicit automatic denial triggers are listed in these chunks.
    • Denials may occur if criteria, dosing, quantity limits, or plan terms are not met.
    Denial Risk

    No explicit denial triggers stated in chunks

    No explicit denial triggers are stated in the provided excerpts; the policy instead cross-references related approvals and requires meeting agent-specific criteria — absence of an explicit trigger in this section does not preclude denials for unmet criteria.

    • Providers should not assume that lack of an explicit trigger means approval — verify all listed criteria and plan terms.
    Denial Risk

    Clinical exclusions and specialist prescribing requirements

    Ensure the patient does not meet the policy’s clinical exclusions (e.g., on antiplatelet/anticoagulant therapy, has a bleeding disorder, or has hepatic impairment) and that the medication is prescribed by or in consultation with the required specialist (e.g., allergist/immunologist, dermatologist for CSU/non-hematology uses; hematologist/oncologist for ITP).

    • Do not prescribe or request coverage if the individual is on antiplatelet/anticoagulant therapy or has a bleeding disorder or hepatic impairment where excluded.
    • Ensure prescribing clinician is the required specialist or provides documentation of specialist consultation.
    Denial Risk

    Safety exclusion triggers — may cause denial

    Requests that involve use in combination with antiplatelet or anticoagulant therapy, or for individuals with bleeding disorders or hepatic impairment (where excluded), may not meet medical necessity criteria and could be denied.

    • Document absence of excluded safety conditions when applicable.
    • If the patient has bleeding risk or hepatic impairment, include justification or do not submit a PA if excluded by policy.
    Denial Risk

    Potential denial triggers (dose, duration, quantity)

    Potential denial triggers include requests that exceed policy-specified dose limits (for example, Brukinsa above the 320 mg daily limit) or requests for initial authorization durations or quantities that are inconsistent with the updated policy limits.

    • Do not request doses above the policy dose limits (e.g., Brukinsa >320 mg daily).
    • Ensure requested initial authorization duration and quantity align with the policy updates.
    Denial Risk

    Denial triggers from limits and plan terms

    Denials may result from plan limits or member benefit terms; providers must verify member coverage because policy guidance does not override plan-specific benefit limitations.

    • Coverage remains subject to member benefit booklet limits and plan terms.
    • Confirm benefit applicability prior to prescribing or submitting PA.
    70 mg capsule: 30 per 30 days; 140 mg capsule: 90 per 30 days; 140/280/420 mg tablet: 30 per 30 days; 70 mg/mL suspension: 216 mL per 30 days
    Policy updateQuantity limits added per 30 days for tablets, capsules, and suspension
    Authorization notePrior authorization required; initial authorization updated to 6 months for most BTK agents
    Rhapsido / Wayrilz — quantity limits
    DrugsRhapsido (remibrutinib); Wayrilz (rilzabrutinib)
    Monthly quantity limit60 tablets per 30 days
    Prescriber/safety notesMedication not used with antiplatelet/anticoagulant therapy; contraindicated in bleeding disorders or hepatic impairment (agent-specific)
    Authorization durationRhapsido and Wayrilz initial authorization updated to 12 months
    Wayrilz — quantity limit (25 mg BID setting)
    DrugWayrilz (rilzabrutinib)
    Monthly quantity limit60 tablets per 30 days
    Non-hematology doseDose limited to 25 mg twice daily for non-hematology immune/dermatology indication
    Prescriber requirementPrescribed by or in consultation with an allergist/immunologist or dermatologist for non-hematology indications
    Brukinsa — quantity limit 60
    DrugBrukinsa (zanubrutinib)
    Monthly quantity limit60 tablets per 30 days
    Dose limitDose limited to 320 mg daily
    Authorization notePrior authorization required; initial authorization updated to 6 months
    Wayrilz — quantity limit 60 (ITP context)
    DrugWayrilz (rilzabrutinib)
    Monthly quantity limit60 tablets per 30 days
    Hematology (ITP) dose notePolicy lists a hematology ITP dose of 400 mg twice daily in one section (document contains inconsistent dose statements)
    Prior therapy requirementFor ITP: insufficient response to corticosteroids, immunoglobulins, rituximab, or splenectomy required
    Imbruvica — quantity limits added (per 30 days)
    DrugImbruvica (ibrutinib)
    Quantity limits addedQuantity limits added per 30 days for tablets, capsules, and suspension (see formulation-specific counts)
    Pediatric cGVHD notecGVHD coverage allowed for age ≥1 year with same formulation limits
    Examples in policyIbrutinib, acalabrutinib, zanubrutinib, pirtobrutinib, remibrutinib, rilzabrutinib
    BTK inhibitors — definition (expanded)
    DefinitionBruton's tyrosine kinase (BTK) inhibitors are small-molecule agents that bind to the intracellular domain of Bruton's kinase and block signaling that drives growth in certain B-cell malignancies and immune-mediated conditions.
    Clinical roleUsed as targeted chemotherapy in hematologic malignancies (e.g., MCL, CLL/SLL, WM, MZL) and select non-oncologic indications included in policy
    Representative agentsAcalabrutinib (Calquence), Ibrutinib (Imbruvica), Zanubrutinib (Brukinsa), Pirtobrutinib (Jaypirca), Remibrutinib (Rhapsido), Rilzabrutinib (Wayrilz)
    Abbreviations
    MCLMantle cell lymphoma
    CLL/SLLChronic lymphocytic leukemia / Small lymphocytic lymphoma
    ITPImmune thrombocytopenia (ITP)
    cGVHDChronic graft-versus-host disease
    Chronic ITP — definition
    ConditionChronic immune thrombocytopenia (ITP)
    DefinitionAn autoimmune disorder with platelet destruction and impaired production; International Working Group threshold: platelet count <100,000 per µL
    Clinical relevanceAssociated with increased bleeding risk; treatment selection considers bleeding risk, prior therapies, and patient factors
    Waldenström's Macroglobulinemia (WM) — definition
    ConditionWaldenström's Macroglobulinemia (WM)
    Cohort stratificationWM cohorts in trials stratified by MYD88 L265P mutation status (MYD88 MUT vs MYD88 WT) relevant to response assessment
    Trial outcome noteASPEN trial did not meet statistical superiority for CR+VGPR in R/R subgroup; used to inform coverage decisions
    BTK inhibitors — example list
    ExamplesIbrutinib (Imbruvica), Acalabrutinib (Calquence), Zanubrutinib (Brukinsa), Pirtobrutinib (Jaypirca), Remibrutinib (Rhapsido), Rilzabrutinib (Wayrilz)
    Class descriptionOral BTK inhibitors used to treat various hematologic malignancies and select immune-mediated conditions as specified in policy
    Policy noteQuantity and dose limits applied to several examples (e.g., 60 tablets/30 days common limit; zanubrutinib dose limit 320 mg daily)
    2024-03-12annual_review

    Annual review updated Jaypirca coverage for certain individuals with CLL/SLL and revised Imbruvica cGVHD pediatric age criteria; added Brukinsa follicular lymphoma indication and clarified FDA dosage/administration applicability and non-formulary exception guidance.

    2025-11-01criteria_added

    Added coverage for Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) after insufficient response to prior treatment.

    2026-02-01criteria_added

    Added coverage criteria for Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU) and removed the prior 2-line plus BCL-2 inhibitor requirement for Jaypirca in relapsed/refractory CLL/SLL.

    2026-05-01operational_update

    Initial authorization periods updated: most BTK agents changed from 3 months to 6 months; Rhapsido (remibrutinib) and Wayrilz (rilzabrutinib) initial authorizations updated to 12 months.

    2026-08-01operational_updateLatest

    Dose and quantity limits updated: Brukinsa dose limited to 320 mg daily and quantity limits added (Brukinsa, Imbruvica, and Wayrilz limited to 60 tablets per 30 days); removed reference to non-formulary exception reviews.

    Key operational and clinical changes recorded in the policy history include: updated initial authorization durations in the 2026 review (most BTK agents: 6 months; remibrutinib and rilzabrutinib: 12 months), an added dose limit for Brukinsa (zanubrutinib) of 320 mg daily, added coverage criteria for rilzabrutinib (Wayrilz) for adults with persistent or chronic immune thrombocytopenia (ITP), and inclusion of REMIX trial evidence supporting remibrutinib (Rhapsido) for chronic spontaneous urticaria. Quantity limits (commonly 60 tablets per 30 days) and formulation-specific limits for ibrutinib were also added or updated.